JP2019528241A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019528241A5 JP2019528241A5 JP2018565671A JP2018565671A JP2019528241A5 JP 2019528241 A5 JP2019528241 A5 JP 2019528241A5 JP 2018565671 A JP2018565671 A JP 2018565671A JP 2018565671 A JP2018565671 A JP 2018565671A JP 2019528241 A5 JP2019528241 A5 JP 2019528241A5
- Authority
- JP
- Japan
- Prior art keywords
- group
- alkyl
- carbon atoms
- groups
- cxcr4 receptor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 claims 28
- 125000004432 carbon atom Chemical group C* 0.000 claims 27
- 108010061299 CXCR4 Receptors Proteins 0.000 claims 17
- 102000012000 CXCR4 Receptors Human genes 0.000 claims 17
- 108010050904 Interferons Proteins 0.000 claims 16
- 102000014150 Interferons Human genes 0.000 claims 16
- 229940079322 interferon Drugs 0.000 claims 16
- 125000000217 alkyl group Chemical group 0.000 claims 13
- 125000003277 amino group Chemical group 0.000 claims 12
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 11
- 239000008194 pharmaceutical composition Substances 0.000 claims 11
- 125000005843 halogen group Chemical group 0.000 claims 10
- 238000000034 method Methods 0.000 claims 7
- 125000003118 aryl group Chemical group 0.000 claims 6
- 230000028327 secretion Effects 0.000 claims 6
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims 5
- 125000001072 heteroaryl group Chemical group 0.000 claims 5
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 claims 4
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims 4
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 claims 4
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims 4
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 claims 4
- 235000001014 amino acid Nutrition 0.000 claims 4
- 229940024606 amino acid Drugs 0.000 claims 4
- 150000001413 amino acids Chemical class 0.000 claims 4
- 235000003704 aspartic acid Nutrition 0.000 claims 4
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 claims 4
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 4
- 210000002865 immune cell Anatomy 0.000 claims 4
- 238000000338 in vitro Methods 0.000 claims 4
- 150000003839 salts Chemical class 0.000 claims 4
- 238000012216 screening Methods 0.000 claims 4
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims 4
- LELOWRISYMNNSU-UHFFFAOYSA-N Hydrocyanic acid Chemical group N#C LELOWRISYMNNSU-UHFFFAOYSA-N 0.000 claims 3
- 125000003545 alkoxy group Chemical group 0.000 claims 3
- 210000000601 blood cell Anatomy 0.000 claims 3
- 125000004093 cyano group Chemical group *C#N 0.000 claims 3
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims 3
- 230000002401 inhibitory effect Effects 0.000 claims 3
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 3
- 239000004475 Arginine Substances 0.000 claims 2
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims 2
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 claims 2
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims 2
- 208000033273 Proteasome-associated autoinflammatory syndrome Diseases 0.000 claims 2
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims 2
- 125000002877 alkyl aryl group Chemical group 0.000 claims 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims 2
- 125000003710 aryl alkyl group Chemical group 0.000 claims 2
- 239000004202 carbamide Substances 0.000 claims 2
- 125000000753 cycloalkyl group Chemical group 0.000 claims 2
- 235000018417 cysteine Nutrition 0.000 claims 2
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims 2
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 claims 2
- 235000013922 glutamic acid Nutrition 0.000 claims 2
- 239000004220 glutamic acid Substances 0.000 claims 2
- 229960001340 histamine Drugs 0.000 claims 2
- 229960000310 isoleucine Drugs 0.000 claims 2
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 claims 2
- 208000017502 proteosome-associated autoinflammatory syndrome Diseases 0.000 claims 2
- -1 scFv antibody Proteins 0.000 claims 2
- ATHGHQPFGPMSJY-UHFFFAOYSA-N spermidine Chemical compound NCCCCNCCCN ATHGHQPFGPMSJY-UHFFFAOYSA-N 0.000 claims 2
- PFNFFQXMRSDOHW-UHFFFAOYSA-N spermine Chemical compound NCCCNCCCCNCCCN PFNFFQXMRSDOHW-UHFFFAOYSA-N 0.000 claims 2
- 208000011580 syndromic disease Diseases 0.000 claims 2
- 125000005309 thioalkoxy group Chemical group 0.000 claims 2
- 239000004474 valine Substances 0.000 claims 2
- OOSUDWRRWZVFEB-UHFFFAOYSA-N (6,6-dimethyl-5h-imidazo[2,1-b][1,3]thiazol-3-yl)methyl n,n'-dicyclohexylcarbamimidothioate Chemical compound C=1SC2=NC(C)(C)CN2C=1CSC(=NC1CCCCC1)NC1CCCCC1 OOSUDWRRWZVFEB-UHFFFAOYSA-N 0.000 claims 1
- OGHPXKAKVMJGQH-UHFFFAOYSA-N 4-(2-aminoethyl)-6-chloro-7-hydroxychromen-2-one 2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.NCCc1cc(=O)oc2cc(O)c(Cl)cc12 OGHPXKAKVMJGQH-UHFFFAOYSA-N 0.000 claims 1
- WVLHHLRVNDMIAR-IBGZPJMESA-N AMD 070 Chemical compound C1CCC2=CC=CN=C2[C@H]1N(CCCCN)CC1=NC2=CC=CC=C2N1 WVLHHLRVNDMIAR-IBGZPJMESA-N 0.000 claims 1
- 108091023037 Aptamer Proteins 0.000 claims 1
- 206010003402 Arthropod sting Diseases 0.000 claims 1
- 201000001320 Atherosclerosis Diseases 0.000 claims 1
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- 208000003014 Bites and Stings Diseases 0.000 claims 1
- 208000010126 Chondromatosis Diseases 0.000 claims 1
- 208000011231 Crohn disease Diseases 0.000 claims 1
- 208000001034 Frostbite Diseases 0.000 claims 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims 1
- 108010014726 Interferon Type I Proteins 0.000 claims 1
- 102000002227 Interferon Type I Human genes 0.000 claims 1
- 108010074328 Interferon-gamma Proteins 0.000 claims 1
- 102000008070 Interferon-gamma Human genes 0.000 claims 1
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 claims 1
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 claims 1
- 201000002481 Myositis Diseases 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 208000021386 Sjogren Syndrome Diseases 0.000 claims 1
- 201000009594 Systemic Scleroderma Diseases 0.000 claims 1
- 206010042953 Systemic sclerosis Diseases 0.000 claims 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims 1
- 208000029265 Type 1 interferonopathy Diseases 0.000 claims 1
- 208000036142 Viral infection Diseases 0.000 claims 1
- 125000005213 alkyl heteroaryl group Chemical group 0.000 claims 1
- 125000003368 amide group Chemical group 0.000 claims 1
- 150000001408 amides Chemical class 0.000 claims 1
- 208000010928 autoimmune thyroid disease Diseases 0.000 claims 1
- 229910052799 carbon Inorganic materials 0.000 claims 1
- 210000004027 cell Anatomy 0.000 claims 1
- 230000001684 chronic effect Effects 0.000 claims 1
- UCAIEVHKDLMIFL-UHFFFAOYSA-N clobenpropit Chemical compound C1=CC(Cl)=CC=C1CNC(=N)SCCCC1=CNC=N1 UCAIEVHKDLMIFL-UHFFFAOYSA-N 0.000 claims 1
- 210000004544 dc2 Anatomy 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 229960003638 dopamine Drugs 0.000 claims 1
- 150000002148 esters Chemical class 0.000 claims 1
- SKTIZSRPCXRDHX-UHFFFAOYSA-N ffn 511 Chemical compound C12=C3CCCN2CCCC1=CC1=C3OC(=O)C=C1CCN SKTIZSRPCXRDHX-UHFFFAOYSA-N 0.000 claims 1
- 125000000623 heterocyclic group Chemical group 0.000 claims 1
- 150000004677 hydrates Chemical class 0.000 claims 1
- 238000000126 in silico method Methods 0.000 claims 1
- 108010018844 interferon type III Proteins 0.000 claims 1
- 206010025135 lupus erythematosus Diseases 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 229910052760 oxygen Inorganic materials 0.000 claims 1
- 210000005134 plasmacytoid dendritic cell Anatomy 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 102000005962 receptors Human genes 0.000 claims 1
- 108020003175 receptors Proteins 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 229940076279 serotonin Drugs 0.000 claims 1
- 229940063673 spermidine Drugs 0.000 claims 1
- 229940063675 spermine Drugs 0.000 claims 1
- 229910052717 sulfur Inorganic materials 0.000 claims 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims 1
- 230000009385 viral infection Effects 0.000 claims 1
- 0 CC(C)(*)CC(C)(C)SC(N(*)*)=N* Chemical compound CC(C)(*)CC(C)(C)SC(N(*)*)=N* 0.000 description 2
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022129702A JP2022166193A (ja) | 2016-06-16 | 2022-08-16 | インターフェロンレベルを低下させるのに有用な化合物 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16305735.9 | 2016-06-16 | ||
| EP16305735 | 2016-06-16 | ||
| PCT/EP2017/064820 WO2017216368A1 (en) | 2016-06-16 | 2017-06-16 | Compounds useful for decreasing interferon level |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022129702A Division JP2022166193A (ja) | 2016-06-16 | 2022-08-16 | インターフェロンレベルを低下させるのに有用な化合物 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2019528241A JP2019528241A (ja) | 2019-10-10 |
| JP2019528241A5 true JP2019528241A5 (enExample) | 2020-07-27 |
Family
ID=56896477
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018565671A Pending JP2019528241A (ja) | 2016-06-16 | 2017-06-16 | インターフェロンレベルを低下させるのに有用な化合物 |
| JP2022129702A Pending JP2022166193A (ja) | 2016-06-16 | 2022-08-16 | インターフェロンレベルを低下させるのに有用な化合物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022129702A Pending JP2022166193A (ja) | 2016-06-16 | 2022-08-16 | インターフェロンレベルを低下させるのに有用な化合物 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20190175557A1 (enExample) |
| EP (1) | EP3471715A1 (enExample) |
| JP (2) | JP2019528241A (enExample) |
| CN (1) | CN109640979A (enExample) |
| CA (1) | CA3027296A1 (enExample) |
| WO (1) | WO2017216368A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11433048B2 (en) * | 2016-06-16 | 2022-09-06 | Centre National De La Recherche Scientifique | CXCR4 receptor-binding compounds useful for increasing interferon level |
| WO2020201096A1 (en) | 2019-03-29 | 2020-10-08 | Université de Paris | Imidazoline derivatives as cxcr4 modulators |
| JP2023543950A (ja) | 2020-09-28 | 2023-10-18 | エルミウム・セラピューティクス | Ｃｘｃｒ４モジュレーターとしての環状イソチオ尿素誘導体 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1999047158A2 (en) * | 1998-03-13 | 1999-09-23 | The University Of British Columbia | Therapeutic chemokine receptor antagonists |
| EP1317451B1 (en) * | 2000-09-15 | 2006-08-09 | Anormed Inc. | Chemokine receptor binding heterocyclic compounds |
| RS58102B1 (sr) * | 2011-11-09 | 2019-02-28 | Bristol Myers Squibb Co | Lečenje hematoloških maligniteta sa anti-cxcr4 antitelom |
-
2017
- 2017-06-16 JP JP2018565671A patent/JP2019528241A/ja active Pending
- 2017-06-16 US US16/310,146 patent/US20190175557A1/en not_active Abandoned
- 2017-06-16 CA CA3027296A patent/CA3027296A1/en active Pending
- 2017-06-16 CN CN201780049535.XA patent/CN109640979A/zh active Pending
- 2017-06-16 EP EP17737213.3A patent/EP3471715A1/en not_active Withdrawn
- 2017-06-16 WO PCT/EP2017/064820 patent/WO2017216368A1/en not_active Ceased
-
2022
- 2022-08-16 JP JP2022129702A patent/JP2022166193A/ja active Pending